Do you just post for the sake of posting non-sense? Vivus's institutional ownership is 77.92% vs 46.06% for Arena. And blackrock/First Manhattan have recently increased their position in Vivus. Qsymia sales are growing at a strong rate and have made substantial progress given the lack of robust insurance coverage. The efficacy has been helpful in establishing steady growth which is going to be a problem for belviq. Belviq had a 60% drop out rate when it was provided free of charge in trials. Whats the drop out rate going to be when people have to pay over 150$/mo for marginal weight loss.